BioSpace News Archive

SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical stage targeted oncology company, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 26,712 shares of common stock and an aggregate of 16,659 restricted stock units (“RSUs”) to three new employees. Each stock option has an exercise pric

EMERYVILLE, Calif. , Feb. 19, 2020 /PRNewswire/ -- Amyris, Inc. (NASDAQ: AMRS), a global science and technology leader of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that its Clean Beauty business comprising Biossance, Pipette and the company’s squalane ingredients business is off to much bette

NeuroHydrate, a healthcare startup, has quietly developed and market-tested HM-Formula, a new non-prescription migraine prevention supplement.

GUILFORD, CONN ., Feb. 19, 2020 /PRNewswire/ -- Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medica

Feb. 19, 2020 13:30 UTC Drug Candidate SK1‑I Shown to Markedly Decrease Lupus-Associated Immune Criteria and Kidney Inflammation in Preclinical Study Study is Further Confirmation of Enzo Biochem’s Proprietary Compound’s Potential for Treatment of this and other Autoimmune Diseases NEW YORK--( BUSINESS WIRE )-- Enzo Biochem, Inc. (NYSE:ENZ) today announced the publication of a study in The FASEB Journal by academic researchers that shows drug candidate “SK1‑I,” the c

Feb. 19, 2020 13:35 UTC ORP-101 Currently in Phase 2 Study for Treatment of Irritable Bowel Syndrome with Diarrhea SAN FRANCISCO--( BUSINESS WIRE )-- OrphoMed, Inc., a clinical-stage biopharmaceutical company, today announced the presentation at Digestive Disease Week ® (DDW) of Phase 1 data for its lead candidate ORP-101, being developed for the treatment of irritable bowel syndrome with diarrhea. Anthony J. Lembo, M.D., Director of the GI Motility and Functional Bowe

Feb. 19, 2020 13:30 UTC Anokion to Present at the 3 rd Antigen Specific Immune Tolerance Summit CAMBRIDGE, Mass. & LAUSANNE, Switzerland--( BUSINESS WIRE )-- Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Stephan Kontos, Ph.D., co-founder and chief scientific officer of Anokion, will give a presentation titled, “Translational & Clinical Development of Novel, Liver Targeted Immune

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Michael Quigley, PhD has joined the company as Senior Vice President, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology.

SpendEdge has been monitoring the global amino acids market and the market is poised to experience spend growth of over USD 8 billion between 2018-2023 at a CAGR of more than 5% during the forecast period.

Feb. 19, 2020 13:30 UTC Viz RECRUIT offers New Algorithms for ICH, Aneurysm Detection and Ischemic Core Volumes, together with improved imaging sharing and collaboration software SAN FRANCISCO--( BUSINESS WIRE )-- Viz.ai, Inc. the leading applied artificial intelligence healthcare company, is excited to announce the expansion of Viz RECRUIT, Viz’s Clinical Trial Platform at the International Stroke Conference in Los Angeles (Feb. 19-21). Viz RECRUIT employs artificial int